Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic

The SARS-CoV-2 coronavirus (COVID-19) pandemic has significantly impacted the delivery of cellular therapeutics, including chimeric antigen receptor (CAR) T cells. This impact has extended beyond patient care to include logistics, administration, and distribution of increasingly limited health care...

Descripción completa

Detalles Bibliográficos
Autores principales: Bachanova, Veronika, Bishop, Michael R., Dahi, Parastoo, Dholaria, Bhagirathbhai, Grupp, Stephan A., Hayes-Lattin, Brandon, Janakiram, Murali, Maziarz, Richard T., McGuirk, Joseph P., Nastoupil, Loretta J., Oluwole, Olalekan O., Perales, Miguel-Angel, Porter, David L., Riedell, Peter A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. 2020
Materias:
Position Statement
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194685/
https://www.ncbi.nlm.nih.gov/pubmed/32298807
http://dx.doi.org/10.1016/j.bbmt.2020.04.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194685/
https://www.ncbi.nlm.nih.gov/pubmed/32298807
http://dx.doi.org/10.1016/j.bbmt.2020.04.008

Ejemplares similares